[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-331937-105":59,"doc-detail-331937-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dark-horse-target-claudin182-opens-new-battlefield-for-pancreatic-cancer-review","Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer - Review","","Pancreatic cancer is presented as a highly lethal malignancy, and Claudin18.2 is highlighted as a tight-junction protein with tight tissue-specific expression that becomes accessible in cancerous states. The manuscript outlines Claudin18.2’s roles in initiation, progression, metastasis, and prognosis, and summarizes ongoing clinical trials targeting Claudin18.2. Coverage includes multiple therapeutic modalities such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR-T cell therapy, with emphasis on integrating current research progress for Claudin18.2-positive pancreatic cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dark-horse-target-claudin182-opens-new-battlefield-for-pancreatic-cancer-review/331937/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dark-horse-target-claudin182-opens-new-battlefield-for-pancreatic-cancer-review/331937.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is Claudin18.2 considered a potential therapeutic target for pancreatic cancer?","Question",{"text":112,"@type":113},"Claudin18.2 is highly expressed in pancreatic cancer and is linked to cancer initiation, progression, metastasis, and prognosis. In cancerous tissues, changes in cell polarity expose the Claudin18.2 epitope, increasing its accessibility to targeted agents.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What roles do claudins play in normal tissue?",{"text":117,"@type":113},"Claudins are proteins in normal tissue tight junctions, supporting intracellular signaling, fence, and barrier functions. They help regulate selective paracellular permeability of ions, water, immune cells, and macromolecules.",{"name":119,"@type":110,"acceptedAnswer":120},"Which treatment approaches targeting Claudin18.2 are discussed?",{"text":121,"@type":113},"The manuscript summarizes ongoing clinical trials involving monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR-T cell therapy for Claudin18.2-positive pancreatic cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},331937,1790705005,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","TYPE Review  \nPUBLISHED 06 March 2024  \nDOI 10.3389/fonc.2024.1371421  \nOPEN ACCESS  \nEDITED BY  \nKathleen E. DelGiorno,  \nVanderbilt University, United States  \nREVIEWED BY Elva Morretta,  \nUniversità degli Studi di Salerno, Italy Mukulika Bose,  \nUniversity of Texas MD Anderson Cancer Center, United States  \n*CORRESPONDENCE Yingjie Jia  \n [1614236405@qq.com](1614236405@qq.com)  \n†These authors have contributed equally to this work  \nRECEIVED 16 January 2024  \nACCEPTED 23 February 2024  \nPUBLISHED 06 March 2024  \nCITATION  \nXu Q, Jia C, Ou Y, Zeng C and Jia Y (2024) Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer.  \nFront. Oncol. 14:1371421 .  \ndoi: 10.3389/fonc.2024.1371421  \nCOPYRIGHT  \n© 2024 Xu, Jia, Ou, Zeng and Jia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nDark horse target Claudin18.2 opens new battlefield for pancreatic cancer  \nQian Xu 1,2†, Caiyan Jia 1,2†, Yan Ou 1,2†, Chuanxiu Zeng 1,2 and Yingjie Jia 1,2*  \n1 Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, 2 Department of Oncology, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China  \nPancreatic cancer is one of the deadliest malignant tumors, which is a serious threat to human health and life, and it is expected that pancreatic cancer may bethe second leading cause of cancer death in developed countries by 2030 . Claudin18.2 is a tight junction protein expressed in normal gastric mucosal tissues, which is involved in the formation of tight junctions between cells and affects the permeability of paracellular cells. Claudin18 . 2 is highly expressed in pancreatic cancer and is associated with the initiation, progression, metastasis and prognosis of cancer, so it is considered a potential therapeutic target. Up to now, a number of clinical trials for Claudin18.2 are underway, including solid tumors such as pancreatic cancers and gastric cancers, and the results of these trials have not yet been officially announced. This manuscript briefly describes the Claudia protein, the dual roles of Cluadin18 in cancers, and summarizes the ongoing clinical trials targeting Claudin18.2 with a view to integrating the research progress of Claudin18 . 2 targeted therapy. In addition, this manuscript introduces the clinical research progress of Claudin18.2 positive pancreatic cancer, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, CAR-T cell therapy, and hope to provide feasible ideas for the clinical treatment of Claudin18 . 2 positive pancreatic cancer.  \nKEYWORDS  \npancreatic cancer, Claudin18.2, targeted therapy, immunotherapy, trials  \n1 Introduction  \nClaudins are important proteins in normal tissue tight junctions (TJ), which are related to the formation of epithelial and epidermal tight junction proteins (1), and were first discovered and named by researchers Mikio Furuse and Shoichiro Tsukita of Kyoto University in Japan in 1998 . The name “Claudin” originated from the Latin word “claudere (to close)” (2) . Three main functions of Claudins are intracellular signaling, fence, and barrier. While the function offence divides the apical and basolateral domains and controls substance mobility in the plasma membrane, the function of barrier is the capacity to  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \ncontrol the paracellular permeation of ions, water, immune cells, and macromolecules, selectively (3–5) . Claudins include at least 27 family members, 4 transmembrane structural domains, a","cbCaihuK2LKxELVA","https://ap.wps.com/l/cbCaihuK2LKxELVA","pdf",1451662,11,"English","# Introduction\n## Claudins and Claudin18.2 background\n## Claudin18.2 expression patterns in cancers\n## Claudin18.2-positive pancreatic cancer evidence\n# Claudin18.2 as a therapeutic target\n# Ongoing clinical trials and therapeutic modalities\n## Monoclonal antibodies\n## Bispecific antibodies\n## Antibody-drug conjugates\n## CAR-T cell therapy","[{\"question\":\"Why is Claudin18.2 considered a potential therapeutic target for pancreatic cancer?\",\"answer\":\"Claudin18.2 is highly expressed in pancreatic cancer and is linked to cancer initiation, progression, metastasis, and prognosis. In cancerous tissues, changes in cell polarity expose the Claudin18.2 epitope, increasing its accessibility to targeted agents.\"},{\"question\":\"What roles do claudins play in normal tissue?\",\"answer\":\"Claudins are proteins in normal tissue tight junctions, supporting intracellular signaling, fence, and barrier functions. They help regulate selective paracellular permeability of ions, water, immune cells, and macromolecules.\"},{\"question\":\"Which treatment approaches targeting Claudin18.2 are discussed?\",\"answer\":\"The manuscript summarizes ongoing clinical trials involving monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR-T cell therapy for Claudin18.2-positive pancreatic cancer.\"}]","Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer - Review | PDF",1789995850,28]